Astellas links up with Anaeropharma on novel anti-tumor drugs

25 September 2018

Japanese firms Anaeropharma Science and Astellas Pharma (TYO: 4503) have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, in situ Delivery and Production System (i-DPS).

Under the terms of the agreement, the two companies will conduct joint research regarding specific substances in order to create drug candidates for cancer therapy that utilizes Bifidobacterium as a drug delivery carrier. No financial terms of the collaboration have been disclosed.

Astellas will acquire the right of first negotiation regarding the exclusive licensing necessary for commercialization based on the results of this joint research. The agreement will not constrain any research and development activities of i-DPS conducted by privately-held Anaeropharma applying to any molecules other than the above-mentioned specific substances.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK